TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856 | Neuropsychopharmacology,日本がん対策図鑑 | 【Clinical Trial 2024】2024年に開始された治験,TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856 | Neuropsychopharmacology,Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study | Schizophrenia,16966-07-7 Z-Thr(tBu)-OH・DCHA | 渡辺化学工業株式会社